The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s) (Q28258363)

Regulatory Toxicology and Pharmacology

Europe PubMed Central

title

The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s) (English)

0 references

author name string

Michael A Dorato

series ordinal

1

0 references

Jeffery A Engelhardt

series ordinal

2

0 references

language of work or name

English

0 references

publication date

August 2005

0 references

published in

0 references

volume

42

0 references

issue

3

0 references

page(s)

265-74

0 references

cites work

"Hormesis"--an inappropriate extrapolation from the specific to the universal

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2005.05.004

Reference dose (RfD): description and use in health risk assessments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2005.05.004

Improvements in quantitative noncancer risk assessment. Sponsored by the Risk Assessment Specialty Section of the Society of Toxicology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2005.05.004

Regulatory decision strategy for entry of a novel biological therapeutic with a clinically unmonitorable toxicity into clinical trials: pre-IND meetings and a case example

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2005.05.004

Does the animal-to-human uncertainty factor incorporate interspecies differences in surface area?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2005.05.004

Improved method for selection of the NOAEL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2005.05.004

Hormesis as a biological hypothesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2005.05.004

Hormesis: a highly generalizable and reproducible phenomenon with important implications for risk assessment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2005.05.004

The hormetic dose-response model is more common than the threshold model in toxicology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2005.05.004

Toxicology rethinks its central belief

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2005.05.004

Hormesis--basic, generalizable, central to toxicology and a method to improve the risk-assessment process

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2005.05.004

Paradigm lost, paradigm found: the re-emergence of hormesis as a fundamental dose response model in the toxicological sciences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2005.05.004

Regulatory history and experimental support of uncertainty (safety) factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2005.05.004

Statistical properties of the NOAEL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2005.05.004

Recognition of adverse and nonadverse effects in toxicity studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2005.05.004

Concordance of the toxicity of pharmaceuticals in humans and in animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2005.05.004

Hormesis and toxicological risk assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2005.05.004

The role of pharmacological profiling in safety assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2005.05.004

The benchmark approach applied to a 28-day toxicity study with Rhodorsil Silane in rats. the impact of increasing the number of dose groups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2005.05.004